Evidence map›Paper›PMID 37580629›Full record

ArticleCardiovascular engineering and technology2023

Transcatheter Pulmonary Artery Banding in High-Risk Neonates: In-Vitro Study Provoked by Initial Clinical Experience.

Shannen B Kizilski, Dominic P Recco, Francesca Sperotto, Nora Lang, Peter E Hammer, Christopher W Baird, Nicola Maschietto, David M Hoganson

Abstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular engineering and technology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shannen B Kizilski *Department of Cardiac Surgery, Harvard Medical School, Boston Children's Hospital, 300 Longwood Avenue, Bader, 2nd Floor, Boston, MA, 02215, USA.ORCID 0000-0003-2447-1969
Dominic P Recco *Department of Cardiac Surgery, Harvard Medical School, Boston Children's Hospital, 300 Longwood Avenue, Bader, 2nd Floor, Boston, MA, 02215, USA.
Francesca SperottoDepartment of Cardiology, Harvard Medical School, Boston Children's Hospital, Boston, MA, USA.
Nora LangDepartment of Cardiology, Harvard Medical School, Boston Children's Hospital, Boston, MA, USA.
Peter E HammerDepartment of Cardiac Surgery, Harvard Medical School, Boston Children's Hospital, 300 Longwood Avenue, Bader, 2nd Floor, Boston, MA, 02215, USA.
Christopher W BairdDepartment of Cardiac Surgery, Harvard Medical School, Boston Children's Hospital, 300 Longwood Avenue, Bader, 2nd Floor, Boston, MA, 02215, USA.
Nicola Maschietto *Department of Cardiology, Harvard Medical School, Boston Children's Hospital, Boston, MA, USA.
David M Hoganson *Department of Cardiac Surgery, Harvard Medical School, Boston Children's Hospital, 300 Longwood Avenue, Bader, 2nd Floor, Boston, MA, 02215, USA. David.Hoganson@cardio.chboston.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeVery high-risk, ductal-dependent or complex two-ventricle patients with associated comorbidities often require pulmonary blood flow restriction as bridge to a more definitive procedure, but current surgical options may not be well-tolerated. An evolving alternative utilizes a fenestrated Micro Vascular Plug (MVP) as a transcatheter, internal pulmonary artery band. In this study, we report a case series and an in-vitro evaluation of the MVP to elicit understanding of the challenges faced with device implantation.

methodsFollowing single-center, retrospective review of eight patients who underwent device placement, an in-vitro flow study was conducted on MVP devices to assess impact of device and fenestration sizing on pulmonary blood flow. A mathematical model was developed to relate migration risk to vessel size. Results of the engineering analysis were compared to the clinical series for validation.

resultsAt median follow-up of 8 months (range 1-15), survival was 63% (5/8), and 6 (75%) patients underwent subsequent target surgical intervention with relatively low mortality (1/6). Occluder-related challenges included migration (63%) and peri-device flow, which were evaluated in-vitro. The device demonstrated durability over normal and supraphysiologic conditions with minimal change in fenestration size. Smaller vessel size significantly increased pressure gradient due to reduced peri-device flow and smaller effective fenestration size.

conclusionDevice oversizing, with appropriate adjustment to fenestration size, may reduce migration risk and provide a clinically appropriate balance between resulting pressure gradient and Qp:Qs. Our results can guide the interventionalist in appropriately selecting the device and fenestrations based on patient-specific anatomy and desired post-implantation flow characteristics.

Indexed as

Cardiac CatheterizationPulmonary ArteryHumansInfant, NewbornRetrospective StudiesTreatment OutcomeCongenital heart diseasePediatric interventionPediatricsPulmonary flow restrictorsStage I palliationTranscatheter

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.